TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE

摘要

The present invention provides a pharmaceutical composition comprising an inhibitor of an NC Ca-ATP channel and a pharmaceutically acceptable carrier for use in a method of preventing or reducing ischemic damage in one or more organs or tissues selected from kidney, wherein
the inhibitor is administered as a loading dose followed by a constant infusion, or
the inhibitor is delivered in a dosage of less than 3.5 mg per day, or
the inhibitor is delivered at a dosage of less than 0.8 mg/kg body weight within a 24 hour period.